CRVS Projected Dividend Yield
Corvus Pharmaceuticals Inc ( NASDAQ : CRVS )Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. Co. is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, a selective, covalent inhibitor of ITK (interleukin 2 inducible T cell kinase) and is in a multi-center Phase 1/1b clinical trial in patients with various recurrent, malignant T cell lymphomas. Soquelitinib is designed to inhibit the proliferation of certain malignant T cells. 21 YEAR PERFORMANCE RESULTS |
CRVS Dividend History Detail CRVS Dividend News CRVS Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |